Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Velzatinib in Participants With Hepatic Impairment
NCT07859735Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Primary completion
- Apr 2028
01
Overview
Phase 1, open-label trial of velzatinib in gastrointestinal neoplasms (4 arms), sponsored by GSK. Primary endpoints: Maximum plasma concentration up to 936 hours, Area under the plasma concentration-time curve extrapolated to infinity up to 936 hours and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
velzatinib
03
Conditions
gastrointestinal neoplasms
Beyond the preview
Go deeper on NCT07859735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859735.